A Phase 1b, open label, prospective, non-randomized,single center study of conditional lethalithy to copper as a therapeutic modality in prostate cancer
Clinical Trial Grant
Awarded By
Cantex Pharmaceuticals, Inc.
Start Date
May 17, 2017
End Date
June 1, 2021
Awarded By
Cantex Pharmaceuticals, Inc.
Start Date
May 17, 2017
End Date
June 1, 2021